PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9179898-1 1997 OBJECTIVE: To determine the capability of donors of nitric oxide (NO) (sodium nitroprusside, nitroglycerine) to reverse endothelin-1 (ET-1)-induced cerebral vasoconstriction in vivo, when administered through the cerebrospinal fluid (CSF) to the adventitial side of the constricted blood vessel. Nitroglycerin 93-107 endothelin 1 Homo sapiens 120-132 10453541-4 1997 In addition, nitroglycerine (2.2 x 10(-3) mol/L) remarkably reduced medium ET-1 levels in cultured endothelial cells, which suggested that nitric oxide might inhibit the secretion of ET-1. Nitroglycerin 13-27 endothelin 1 Homo sapiens 75-79 10453541-4 1997 In addition, nitroglycerine (2.2 x 10(-3) mol/L) remarkably reduced medium ET-1 levels in cultured endothelial cells, which suggested that nitric oxide might inhibit the secretion of ET-1. Nitroglycerin 13-27 endothelin 1 Homo sapiens 183-187 9179898-1 1997 OBJECTIVE: To determine the capability of donors of nitric oxide (NO) (sodium nitroprusside, nitroglycerine) to reverse endothelin-1 (ET-1)-induced cerebral vasoconstriction in vivo, when administered through the cerebrospinal fluid (CSF) to the adventitial side of the constricted blood vessel. Nitroglycerin 93-107 endothelin 1 Homo sapiens 134-138 9179898-6 1997 RESULTS: Sodium nitroprusside and nitroglycerine, both donors of NO, rapidly and completely reversed ET-1-induced vasoconstriction without causing hypotension. Nitroglycerin 34-48 endothelin 1 Homo sapiens 101-105 8682599-3 1996 In internal mammary and gastroepiploic arteries, the nitrovasodilators, sodium nitroprusside and glyceryl trinitrate, effectively reversed the spasms induced either with noradrenaline (for sodium nitroprusside; internal mammary artery: 101.07% +/- 1.63%; gastroepiploic artery: 94.10% +/- 2.07%) or endothelin-1 (for sodium nitroprusside; internal mammary artery: 97.67% +/- 4.94%; gastroepiploic artery: 90.69% +/- 2.61%). Nitroglycerin 97-116 endothelin 1 Homo sapiens 299-311 7888288-5 1994 This study was designed to investigate the effect of glyceryl trinitrate (GTN) and calcium antagonists on ET-1 contraction in the human IMA. Nitroglycerin 53-72 endothelin 1 Homo sapiens 106-110 7815811-8 1995 Nitroglycerin reversed vasoconstriction produced by endothelin-1 and endothelin-1 plus norepinephrine both before and after ischemia-reperfusion. Nitroglycerin 0-13 endothelin 1 Homo sapiens 52-64 7815811-8 1995 Nitroglycerin reversed vasoconstriction produced by endothelin-1 and endothelin-1 plus norepinephrine both before and after ischemia-reperfusion. Nitroglycerin 0-13 endothelin 1 Homo sapiens 69-81 7815811-11 1995 Nitroglycerin reverses coronary vasoconstriction induced by endothelin-1 and may therefore be beneficial in the postoperative management of neonates after cardiac operations. Nitroglycerin 0-13 endothelin 1 Homo sapiens 60-72 7888288-5 1994 This study was designed to investigate the effect of glyceryl trinitrate (GTN) and calcium antagonists on ET-1 contraction in the human IMA. Nitroglycerin 74-77 endothelin 1 Homo sapiens 106-110 7888288-10 1994 In separate experiments, the concentration-relaxation curves to GTN or nifedipine were established in the IMA rings precontracted with ET-1 (10 nM). Nitroglycerin 64-67 endothelin 1 Homo sapiens 135-139 7888288-15 1994 On the other hand, GTN caused 76.44 +/- 6.35% relaxation in ET-1-precontracted IMA. Nitroglycerin 19-22 endothelin 1 Homo sapiens 60-64 1813669-3 1991 Nitroglycerin, a vasorelaxant, completely reverses the ET-induced phosphorylation of MLC, but not that of caldesmon. Nitroglycerin 0-13 endothelin 1 Homo sapiens 55-57 8304511-3 1994 Under control conditions, nitroglycerin caused potent dilations of large (> 200 microns diam) coronary microvessels while having minimal effects on small (< 100 microns diam) coronary microvessels [peak relaxations 85 +/- 4 vs. 23 +/- 3% (mean +/- SE) of endothelin-1-constricted vessels, respectively]. Nitroglycerin 26-39 endothelin 1 Homo sapiens 261-273 8185413-2 1993 KRN2391, nitroglycerin and cromakalim concentration-dependently inhibited the 10(-8) M endothelin-1-induced contraction, but less potently inhibited the 40 mM KCl-induced contraction. Nitroglycerin 9-22 endothelin 1 Homo sapiens 87-99 8185413-4 1993 KRN2391 and nitroglycerin produced a complete relaxation of arteries contracted by endothelin-1 at its maximum effect. Nitroglycerin 12-25 endothelin 1 Homo sapiens 83-95 7509975-5 1993 Although GTN partially prevented ET-1-induced constriction (maximum 33 +/- 5%, p = 0.004 versus ET-1), inhibition of NOS did not affect ET-1-induced venoconstriction (maximum 55 +/- 4%). Nitroglycerin 9-12 endothelin 1 Homo sapiens 33-37 8185413-7 1993 The combination of cromakalim and nitroglycerin relaxed the 10(-8) M endothelin-1- and 40 mM KCl-induced contractions in a concentration-dependent manner. Nitroglycerin 34-47 endothelin 1 Homo sapiens 69-81 8185413-9 1993 The maximum relaxation of the combination of cromakalim (3 x 10(-5) M) and nitroglycerin (3 x 10(-6) M) was complete for the endothelin-1-induced contraction but a relaxation of 77.8% was obtained for the 40 mM KCl-induced contraction, i.e. the relaxant effects using this combination were greater than those by cromakalim (3 x 10(-5) M) alone. Nitroglycerin 75-88 endothelin 1 Homo sapiens 125-137 1733199-6 1992 Nitric oxide generated by addition of glyceryl trinitrate (10(-6) mol/L) attenuated the vasoconstrictor effects of U46619 (p less than 0.026) or endothelin-1 (p less than 0.01). Nitroglycerin 38-57 endothelin 1 Homo sapiens 145-157 11751199-7 2002 Transplanted lung graft ET-1 mRNA, measured by Northern blotting and in situ hybridization, and protein, measured by Western blotting and immunohistochemistry, were suppressed only with Early NTG (P < 0.05 versus all other groups). Nitroglycerin 192-195 endothelin 1 Homo sapiens 24-28 2175599-1 1990 Atrial natriuretic peptide (ANP) and the nitrovasodilator drugs nitroglycerine and nitroprusside were shown here to decrease both basal and thrombin stimulated production of endothelin-1 (ET-1) from cultured human endothelial cells as measured by radioimmunoassay. Nitroglycerin 64-78 endothelin 1 Homo sapiens 188-192 2175599-4 1990 Part of the vasodilatory action of ANP, nitroprusside and nitroglycerine may be due to suppression of endothelial ET-1 production. Nitroglycerin 58-72 endothelin 1 Homo sapiens 114-118 17488313-7 2007 When ET-1 was used as a constrictor nitroglycerin and milrinone caused nearly complete (80-100%) relaxation, whereas other agents were of limited effectiveness (40-50%). Nitroglycerin 36-49 endothelin 1 Homo sapiens 5-9 17488313-9 2007 CONCLUSIONS: Nitroglycerin and milrinone are very effective in reversing ET-1 and U46619-induced pulmonary vasoconstriction in vitro. Nitroglycerin 13-26 endothelin 1 Homo sapiens 73-77 11751199-3 2002 Because endothelin-1 (ET-1), a potent vasoconstrictor, and nitric oxide (NO) are reciprocally regulated in vitro, we hypothesized that early administration of the NO donor NTG may suppress ET-1 and thereby improve lung preservation. Nitroglycerin 172-175 endothelin 1 Homo sapiens 8-20 11751199-3 2002 Because endothelin-1 (ET-1), a potent vasoconstrictor, and nitric oxide (NO) are reciprocally regulated in vitro, we hypothesized that early administration of the NO donor NTG may suppress ET-1 and thereby improve lung preservation. Nitroglycerin 172-175 endothelin 1 Homo sapiens 22-26 11751199-3 2002 Because endothelin-1 (ET-1), a potent vasoconstrictor, and nitric oxide (NO) are reciprocally regulated in vitro, we hypothesized that early administration of the NO donor NTG may suppress ET-1 and thereby improve lung preservation. Nitroglycerin 172-175 endothelin 1 Homo sapiens 189-193 2175599-1 1990 Atrial natriuretic peptide (ANP) and the nitrovasodilator drugs nitroglycerine and nitroprusside were shown here to decrease both basal and thrombin stimulated production of endothelin-1 (ET-1) from cultured human endothelial cells as measured by radioimmunoassay. Nitroglycerin 64-78 endothelin 1 Homo sapiens 174-186 22256559-13 2011 In the NTG patients, significant increase in the mean ET-1 concentration and decrease in the mean NPY concentration seen after the cold-pressor test were accompanied by a significant decrease in the mean MS (mean retinal sensitivity) value in the second eye examined after the cold-pressor test, but no correlation was found between changes in the MS values and changes in the ET-1 and NPY concentrations. Nitroglycerin 7-10 endothelin 1 Homo sapiens 54-58 22256559-13 2011 In the NTG patients, significant increase in the mean ET-1 concentration and decrease in the mean NPY concentration seen after the cold-pressor test were accompanied by a significant decrease in the mean MS (mean retinal sensitivity) value in the second eye examined after the cold-pressor test, but no correlation was found between changes in the MS values and changes in the ET-1 and NPY concentrations. Nitroglycerin 7-10 endothelin 1 Homo sapiens 377-389 22256559-15 2011 CONCLUSIONS: Our findings suggest abnormal neuro-endothelial mechanisms of vascular tone control in NTG patients, related to the effects of ET-1 and NPY, secondary to endothelial dysfunction and to dysregulation of the autonomic nervous system. Nitroglycerin 100-103 endothelin 1 Homo sapiens 140-152 19808370-10 2009 Judged against the response to nitroglycerin, ET-1 accounted for 53.2% of coronary tone in advanced TCA but only 12.9% without advanced TCA. Nitroglycerin 31-44 endothelin 1 Homo sapiens 46-50 11751199-8 2002 Post-transplantation benefits of NTG are restricted to lung grafts which received NTG during the early harvest and immersion periods, and are coincident with suppression of graft ET-1 expression. Nitroglycerin 33-36 endothelin 1 Homo sapiens 179-183 11751199-9 2002 When viewed in the context of improved graft survival and function with ET-1 receptor blockade, these data suggest that early administration of NTG to donor lungs improves primary graft function, in part, by suppressing graft ET-1 expression. Nitroglycerin 144-147 endothelin 1 Homo sapiens 72-76 11751199-9 2002 When viewed in the context of improved graft survival and function with ET-1 receptor blockade, these data suggest that early administration of NTG to donor lungs improves primary graft function, in part, by suppressing graft ET-1 expression. Nitroglycerin 144-147 endothelin 1 Homo sapiens 226-230 11574422-5 2001 Likewise, downstream of ERK1/2, ET-1 stimulated Elk-1-driven GAL4 luciferase activity to 11 +/- 1-fold (P < 0.002 vs. NG + ET-1) in HG, and DN-PKC-delta, -epsilon, or -zeta attenuated this response to NG levels. Nitroglycerin 121-123 endothelin 1 Homo sapiens 32-36